Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orziloben (NST-6179) in Subjects With Intestinal Failure-Associated Liver Disease (IFALD)

NCT05919680 is registered in ClinicalTrials.gov with NorthSea Therapeutics B.V. as lead sponsor.

NCT NCT05919680
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05919680 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orziloben (NST-6179) in Subjects With Intestinal Failure-Associated Liver Disease (IFALD)
Lead sponsor
NorthSea Therapeutics B.V.
Phase
Phase 2
Overall status
Recruiting
Start date
January 15, 2024
Completion date
June 30, 2025
Enrollment
36 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

intestinal failure associated liver disease